The control method of a ventilation of the interior of a motor vehicle, as a function of at least a switching threshold of the concentration of harmful components.

PROCESS Of OBTURATION Of an OPENING CROSSED BY a PLURALITY OF CABLES

A control method of a device for ventilating the interior of a motor vehicle, depending on concentrations of air pollutants of the exterior and interior.

PROPANSÄUREDERIVATE, DIE DIE BINDUNG VON INTEGRINEN AN IHRE REZEPTOREN BEHINDERN

RIECHSTOFF-ZUSAMMENSETZUNGEN

Verfahren und Vorrichtung zum Spruehen mit Hochfrequenz

Zahnärztliche Vakuumeinrichtung

Fuer einen Amplituden-Analysator vorschaltbarer Wandler

METHOD AND APPARATUS FOR IMPLEMENTING SECURITY MEASURES ON NETWORK DEVICES

A method for providing security measures on a network device, such as a router, is disclosed. In one embodiment, a method includes receiving a request for a network resource. The method further includes determining a classification of the request, and generating, based on the determined classification of the request, a security measure corresponding to the determined classification of the request for authentication of the request. The method also includes permitting access to the network resource when a correct response is received to the security measure corresponding to the determined classification of the request. 1. A computer-implemented method comprising:receiving a request for a network resource;determining a classification of the request;generating, based on the determined classification of the request, a security measure corresponding to the determined classification of the request for authentication of the request; andpermitting access to the network resource when a correct response is received to the security measure corresponding to the determined classification of the request.2. The method of claim 1 , wherein the request for the network resource is a request for an administrative page of configuration settings of a router.3. The method of claim 1 , further comprising:detecting a user agent of a software application issuing the request for the network resource; anddetermining whether the detected user agent represents a trusted software application;wherein the request is classified as a trusted request if the detected user agent represents a trusted software application, and the request is classified as non-trusted if the detected user agent does not represent a trusted software application.4. The method of claim 3 , wherein the generated security measure corresponding to a trusted request uses a challenge-response protocol for programmatically performing authentication of the request.5. The method of claim 4 , wherein the challenge-response protocol is ...

PERSONALIZED PRODUCTION OF BIOLOGICS AND METHOD FOR REPROGRAMMING SOMATIC CELLS

The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation. 1. A method for producing a recombinant polypeptide or protein comprising transfecting a synthetically-produced Pluripotent Stem Cell (spPSC) or an endogenous Pluripotent Stem Cell (ePSC) with a nucleic acid that encodes for said polypeptide or protein , under conditions wherein the polypeptide or protein is expressed by said stem cell , wherein the spPSC or ePSC is produced or isolated from a cell of an animal.2. The method of wherein the polypeptide or protein is selected from the group consisting of erythropoietin claim 1 , factor VIII claim 1 , factor IX claim 1 , thrombin claim 1 , an antibody or antibody fragment claim 1 , alpha interferon claim 1 , interferon alpha 2A and 2B claim 1 , beta interferon claim 1 , growth hormone claim 1 , antihemophilic factor claim 1 , G-CSF claim 1 , GM-CSF claim 1 , a soluble receptor claim 1 , TGF-β claim 1 , bone morphogenic proteins (BMP) claim 1 , TGFα claim 1 , interleukin 2 claim 1 , β-glucocerebrosidase or an analogue thereof claim 1 , alpha1-proteinase inhibitor claim 1 , fibrin claim 1 , fibrinogen claim 1 , von Willebrand factor claim 1 , imiglucerase claim 1 , ...

FGF HOMOLOGS COMPOSITIONS AND USES THEREOF

The present invention relates to zFGF5 compositions and methods of using the compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed. 1. An isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID. NO:2 from amino acid residue 28 to residue 175.2. The isolated polynucleotide molecule according to claim 1 , wherein said nucleotide sequence encodes a polypeptide with an initial Met residue.3. The isolated polynucleotide molecule according to claim 1 , wherein the polynucleotide is DNA.4. An expression vector comprising the following operably linked elements:a transcription promoter;{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'a DNA segment according to ; and'}a transcription terminator.5. The expression vector according to claim 4 , wherein the DNA segment encodes a polypeptide with an initial Met residue.6. A cultured cell into which has been introduced an expression vector according to claim 5 , wherein said cell expresses a polypeptide encoded by the DNA segment.7. The cultured cell according to claim 6 , wherein the DNA segment encodes a polypeptide with an initial Met residue.8. A method of producing an FGF homolog polypeptide comprising:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, '(a) culturing a cell into which has been introduced an expression vector according to , whereby said cell expresses an FGF homolog polypeptide encoded by the DNA segment; and'}(b) recovering the FGF homolog polypeptide.9. The method according to claim 8 , wherein the DNA segment ...

COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b). 111-. (canceled)12. A method of reducing inflammation in cardiomyopathy , comprising administering to a subject having cardiomyopathy a composition comprising an antibody that specifically binds a human IL-17 receptor of SEQ ID NO:4 and inhibits human IL-17 of SEQ ID NO:2 from binding said receptor.13. The method of claim 12 , wherein the composition further comprises a pharmaceutically acceptable diluent.14. The method of claim 13 , wherein the composition is administered by injection.15. A method of reducing inflammation in cardiomyopathy claim 13 , comprising administering to a subject having cardiomyopathy a composition comprising an antibody that specifically binds human IL-17 of SEQ ID NO:2 and inhibits said 1L-17 from binding a human IL-17 receptor SEQ ID NO:4.16. The method of claim 15 , wherein the composition further comprises a pharmaceutically acceptable diluent.17. The method of claim 16 , wherein the composition is administered by injection. This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application Ser. No. 60/494,457, filed Aug. 12, 2003, and U.S. Provisional Application Ser. No. 60/406,418, filed Aug. 28, 2002.Embodiments of the invention pertain to compositions and methods for treating ...

ELUTING MEDICAL DEVICES

The invention is directed to eluting medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site. 1. A medical device comprising:a. an expandable member;b. a coating comprising a therapeutic agent disposed around said expandable member;c. a sheath disposed around said coating, wherein said sheath has a variably permeable microstructure that initially limits unintended transfer of therapeutic agent through said sheath when said sheath has a substantially closed microstructure;d. wherein said coating and therapeutic agent are disposed substantially between the surface of the expandable member and the sheath; ande. wherein when said expandable member and sheath are expanded, said sheath has an open microstructure and allows the transfer of said therapeutic agent to an area external to said sheath.2. The medical device of claim 1 , wherein said coating and therapeutic agent are transferred to an area external to said sheath.3. The medical device of claim 1 , wherein said sheath allows for rapid transfer of said coating and therapeutic agent to an area external to the sheath.4. The medical device of claim 1 , wherein said outer sheath is treated with a wetting agent.5. The medical device of claim 4 , wherein said wetting agent is selected from the group consisting of heparin coatings polyvinyl alcohol claim 4 , polyethylene glycol claim 4 , polypropylene glycol claim 4 , dextran claim 4 , agarose claim 4 , alginate claim 4 , ...

ELUTING MEDICAL DEVICES

The invention is directed to eluting medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site. 1. A medical device comprising:a. an expandable member;b. a coating comprising a therapeutic agent disposed around said expandable member;c. a sheath having an inner surface and an outer surface wherein said sheath comprises a variably permeable microstructure that initially limits unintended transfer of said therapeutic agent through said sheath when said sheath has a substantially closed microstructure;d. wherein said coating is disposed on the inner surface of said sheath; ande. wherein when said expandable member and sheath are expanded, said sheath has an open microstructure and allows the transfer of said therapeutic agent to an area external to said sheath.2. The medical device of claim 1 , wherein said coating and therapeutic agent are transferred to an area external to said sheath.3. The medical device of claim 1 , wherein said sheath allows for rapid transfer of said coating and therapeutic agent to an area external to the sheath.4. The medical device of claim 1 , wherein said outer sheath is treated with a wetting agent.5. The medical device of claim 4 , wherein said wetting agent is selected from the group consisting of heparin coatings polyvinyl alcohol claim 4 , polyethylene glycol claim 4 , polypropylene glycol claim 4 , dextran claim 4 , agarose claim 4 , alginate claim 4 , polyacrylamide claim 4 , ...

Utilizing a Ribbon to Access an Application User Interface

A ribbon for accessing an application user interface may be provided. The ribbon may be displayed on a computer in association with the application user interface. The ribbon may include a horizontal scrolling gallery. The horizontal scrolling gallery may display a subset of available options which may be utilized to perform one or more actions with respect to content displayed in the application user interface. An input may be received by the computer to navigate through the available options in the horizontal scrolling gallery. 1. A computer-implemented method for utilizing a ribbon to access an application user interface , comprising:displaying, by a computer, the ribbon, the ribbon comprising a horizontal scrolling gallery displaying a subset of available options, the options being utilized to perform one or more actions in the application user interface; andreceiving, by the computer, an input to navigate through all of the available options in the horizontal scrolling gallery.2. The method of claim 1 , wherein displaying the ribbon comprises displaying a ribbon region and a title bar region.3. The method of claim 2 , wherein displaying the ribbon region comprises displaying the horizontal scrolling gallery.4. The method of claim 3 , further comprising displaying a plurality of scrolling paddles adjacent to the horizontal scrolling gallery upon receiving a hover action by a pointing device in communication with the computer.5. The method of claim 3 , wherein displaying the ribbon region comprises displaying a plurality of tabs.6. The method of claim 5 , wherein displaying the plurality of tabs comprises displaying one or more contextual tabs claim 5 , the one or more contextual tabs being displayed only upon a selection of a piece of content in the application user interface.7. The method of claim 3 , wherein displaying the ribbon region comprises displaying a refresh control for updating the available options displayed in the horizontal scrolling gallery.8. ...

COMPOSITIONS AND METHODS FOR TREATING CARDIVASCULAR DISEASE

The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. 1. A method of reducing inflammation in cardiomyopathy , comprising administering to a subject having cardiomyopathy a composition comprising an antibody that specifically binds human IL-17 comprising SEQ ID NO:2 and inhibits said IL-17 from binding a human IL-17 receptor comprising SEQ ID NO:4.2. The method of claim 1 , wherein the antibody is a monoclonal antibody.3. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable diluent.4. The method of claim 2 , wherein the composition further comprises a pharmaceutically acceptable diluent.54. The method of - claims 1 , wherein the composition is administered by injection. This application is a divisional of U.S. patent application Ser. No. 13/533,727, filed Jun. 26, 2012, now allowed, which is a continuation of U.S. patent application Ser. No. 10/646,308, filed Aug. 21, 2003, now abandoned, which claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application Ser. No. 60/494,457, filed Aug. 12, 2003, and U.S. Provisional Application Ser. No. 60/406,418, filed Aug. 28, 2002.The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 3432-US-DIV_Seq_List.txt, created Aug. 7, 2013, which is 129 KB in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.Embodiments of the invention pertain to compositions and methods for treating cardiovascular disease by modulating inflammatory ...

Retractable sheath devices, systems, and methods

The invention is directed to delivery medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises retractable sheath comprising neckable elements. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and a retractable outer sheath with a selectively permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during retraction of the outer sheath, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A coating comprising:a tetrafluoroethylene copolymer mixed with a water soluble agent,wherein the coating has at least a 50% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as compared with a coating of tetrafluoroethylene copolymer with no water soluble agent.2. The coating of claim 1 , wherein the coating has at least an 80% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as compared with a coating of tetrafluoroethylene copolymer with no water soluble agent.3. The coating of claim 1 , wherein said tetrafluoroethylene copolymer comprises a functional group selected from a group consisting of acetate claim 1 , alcohol claim 1 , amine claim 1 , and amide.4. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl acetate) (TFE-VAc).5. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl alcohol) (TFE-VOH).6. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl alcohol-co-vinyl[aminobutyraldehyde acetal(TFE-VOH-AcAm).7. The coating of 1 claim 1 , wherein said water soluble agent is a therapeutic agent.9. A coating comprising:a tetrafluoroethylene copolymer mixed with a water soluble agent,wherein the coating is phase mixed as measured by modulated differential scanning calorimetry.10. The coating of claim 9 , wherein the coating has at least a 50% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as a PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A method of preparing a water in solvent emulsion comprising the steps of: a. dissolving a tetrafluoroethylene copolymer in a water miscible organic solvent , b. providing a water phase , c. dissolving an agent comprising one of a water soluble agent and a hydrophobic agent , d. combining the tetrafluoroethylene copolymer with the dissolved agent , such that the emulsion is kinetically stable.2. The method of claim 1 , wherein said agent is a therapeutic agent.3. The method of claim 1 , wherein said agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.4. The method of claim 1 , wherein said agent is a water soluble agent which is dissolved into the water phase.5. A method of coating a substrate comprising a water-in-solvent emulsion comprising the steps of: a. providing a water in solvent emulsion comprising a tetrafluoroethylene copolymer claim 1 , a solvent phase comprising a water miscible organic solvent claim 1 , an agent comprising one of a water soluble agent and a hydrophobic agent claim 1 , a water phase claim 1 , wherein said emulsion is kinetically stable; b. applying the water-in-solvent emulsion to the substrate; and c. removing the solvent and water.6. The method of claim 5 , wherein said agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.7. The method of claim 5 , wherein said water phase is <500 nm by Raman spectroscopy.8. The method of claim 5 , wherein said tetrafluoroethylene copolymer comprises functional groups selected from a group ...

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A method for preparing a medical device according to claim 1 , which comprises the steps of combining the therapeutic agent and the at least one organic additive in powder form claim 1 , and then applying the powder to the device to form a solid particulate composition and optionally applying a subsequent thermal treatment step. The present invention relates to solid paclitaxel compositions, medical devices with coatings comprising solid paclitaxel compositions and to ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A method of preparing a water in solvent emulsion comprising the steps of:a. Dissolving a tetrafluoroethylene copolymer in a water miscible organic solvent;b. Providing a water phase;c. Dissolving an agent comprising one of a water soluble agent and a hydrophobic agent; andd. Combining the tetrafluoroethylene copolymer with the dissolved agent, such that the emulsion is kinetically stable.2. The method of claim 1 , wherein the agent is a therapeutic agent.3. The method of claim 1 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.4. The method of claim 1 , wherein the agent is a water soluble agent which is dissolved into the water phase.5. A method of coating a substrate comprising a water-in-solvent emulsion claim 1 , the method comprising the steps of:a. Providing a water in solvent emulsion comprising a tetrafluoroethylene copolymer, a solvent phase comprising a water miscible organic solvent, an agent comprising one of a water soluble agent and a hydrophobic agent, a water phase, wherein the emulsion is kinetically stable;b. Applying the water-in-solvent emulsion to the substrate; andc. Removing the solvent and water.6. The method of claim 5 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.7. The method of claim 5 , wherein the water phase is less than about 500 nm by Raman spectroscopy.8. The method of claim 5 , wherein the tetrafluoroethylene copolymer comprises functional groups selected from a group consisting of ...

IMPLANTABLE MEDICAL DEVICE

According to the invention there is provided inter alia an implantable medical device with coatings comprising an immobilized heparin moiety and elutable paclitaxel and to methods for making such devices. 1. An implantable medical device with a surface having a coating comprising:a first coating layer comprising an immobilized heparin moiety and a second particulate coating layer comprising elutable paclitaxel and at least one organic additive, wherein at least a portion of the second particulate coating layer is in contact with at least a portion of the first coating layer.2. An implantable medical device according to claim 1 , wherein the medical device is a tubular medical device.3. An implantable medical device according to claim 1 , wherein the first coating layer comprises a polymer.4. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently attached to the polymer.5. An implantable medical device according to or claim 4 , wherein the polymer is a cationic polymer.6. An implantable medical device according to claim 5 , wherein the first coating layer comprises one or more coating bilayers of cationic polymer and anionic polymer claim 5 , the innermost layer being a layer of cationic polymer and the outermost layer being the layer of cationic polymer to which the heparin moiety is covalently attached.7. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently end-point attached to the polymer and wherein the end-point attached heparin moiety is connected through its reducing end.8. (canceled)9. (canceled)10. An implantable medical device according to claim 1 , wherein the or each organic additive is non-polymeric and hydrolytically stable.11. (canceled)12. An implantable medical device according to claim 1 , wherein at least a proportion of the second particulate coating layer comprising paclitaxel and at least one organic additive melts as a single phase at a lower temperature than the ...

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

IMPROVED PEPPER PLANTS

The present invention provides methods of preparing a cultivated pepper plant bearing fruit having a low destemming force, as well as methods of preparing a cultivated pepper plant bearing clustered fruit. The invention also provides cultivated pepper plants prepared by these methods. 1. A method of preparing a cultivated pepper plant bearing fruit having a low destemming force , the method comprising:crossing a first parent pepper plant with a second parent pepper plant bearing fruit with a low destemming force; andselecting progeny plants bearing fruit having a lower destemming force as compared to fruit from the first parent pepper plant.2. The method of claim 1 , wherein the second parent pepper plant is UCD-14.3. The method of claim 1 , wherein the step of selecting the progeny plants is carried out by measuring destemming force using a straight pull with a force gauge.4. The method of claim 3 , wherein progeny plants bearing fruit having a mean destemming force of less than 30 N are selected.5. The method of claim 1 , wherein the step of selecting the progeny plants is carried out by measuring destemming force using a torque watch gauge.6. The method of claim 5 , wherein progeny plants bearing fruit having a mean destemming force of less than 40 N are selected.7. The method of wherein the step of selecting includes selecting a plant having a favorable allele identified in Table 1 or Table 4.8. The method of wherein second parent pepper plant has one or more (e.g. claim 1 , all) favorable allele identified in Table 1 or Table 4.9. The method of claim 1 , wherein the second parent pepper plant is heterozygous or homozygous for an allele of UCD-14 from a region of chromosome 2 and 4; or 2 and 10; or 2 and 4 and 10; or 3 and 10; or 2 and 3 and 4 and 10 claim 1 , wherein the region is as defined in Table 3A.10. The method of claim 9 , wherein the second parent pepper plant is heterozygous or homozygous for an allele of Maor from a region of chromosome 7 claim 9 , ...

TELEVISION SCHEDULE SYSTEM AND METHOD OF OPERATION FOR MULTIPLE PROGRAM OCCURRENCES

An improved television guide system. According to one embodiment of the invention, television guide information is provided that includes multiple occurrences of a single show. The guide system of the present invention allows the user to identify a show and, thereafter, identify when the identified show will be played again. Accordingly, the user may more easily select shows for viewing or recordation. 1. (canceled)2. A method for determining that a program is accessible from a broadcast source , the method comprising:generating a display of a plurality of non-broadcast program listings associated with a plurality of programs accessible from a non-broadcast source;receiving a user selection of a first non-broadcast program listing of the plurality of non-broadcast program listings in the generated display;determining, based on information corresponding to the broadcast source, that the program associated with the first non-broadcast program listing is accessible from the broadcast source; andcausing an indication that the program is accessible from the broadcast source to be displayed.3. The method of claim 2 , wherein the non-broadcast source comprises an Internet source.4. The method of claim 2 , wherein the non-broadcast source comprises a video vendor source.5. The method of claim 2 , wherein the indication comprises information identifying an occurrence of the program accessible from the broadcast source.6. The method of claim 2 , further comprising recording an occurrence of the program accessible from the broadcast source responsive to a user selection of the indication.7. The method of claim 2 , wherein the information corresponding to the broadcast source is received from the broadcast source.8. The method of claim 2 , wherein the information corresponding to the broadcast source is received from the non-broadcast source.9. A method for determining that a program is accessible from a non-broadcast source claim 2 , the method comprising:generating a display ...

QUINOLINE-BASED PROTEASOME INHIBITORS AND USES THEREOF

Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation. 1. (canceled)3. The compound of claim 2 , wherein R claim 2 , Ror Ris lower alkyl.4. The compound of claim 2 , wherein R claim 2 , Ror Ris methyl.5. The compound of claim 2 , wherein Ris hydrogen claim 2 , lower alkyl claim 2 , lower alkoxy claim 2 , N claim 2 ,N-dimethylamino or a heterocyclyl group optionally containing one additional heteroatom.6. The compound of claim 2 , wherein Ris methyl claim 2 , isopropyl butyl or methoxy.7. The compound of claim 2 , wherein Ris piperidinyl or a morpholinyl group.9. The compound of claim 8 , wherein R claim 8 , Ror Ris lower alkyl.10. The compound of claim 8 , wherein R claim 8 , Ror Ris methyl.12. A pharmaceutical composition comprising one or more compounds of and one or more pharmaceutically acceptable excipients.13. A pharmaceutical composition comprising one or more compounds of and one or more pharmaceutically acceptable excipients.14. A pharmaceutical composition comprising one or more compounds of and one or more pharmaceutically acceptable excipients.15. A method for treating cancer or an inflammatory disease claim 2 , the comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.16. A method for treating cancer or an inflammatory disease claim 8 , the comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.17. A method for treating cancer or an inflammatory disease claim 11 , the comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.18. A method for modulating proteasome function comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.19. A method for modulating proteasome function comprising administering a therapeutically ...

TELEVISION CONTROL INTERFACE WITH ELECTRONIC GUIDE

An on-screen menu method and system for controlling the functions of integrated electronic devices and a television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel at each time during the day and an interconnected series of menus to control the features of the integrated electronic devices. An input device allows the viewer to move a pointer over different interactive areas of the guide and the function performed when the area is activated is displayed in a contextual help window. Various control glyphs provide for recursive interaction with the guide. 118-. (canceled)19. A method for using an interactive program guide comprising:generating for display a display of the interactive program guide comprising a first plurality of menu options, wherein the first plurality of menu options is displayed over a television program;receiving a user selection of a first menu option of the first plurality of menu options; andin response to receiving the user selection, generating for display an overlay comprising a portion of an e-mail, wherein the overlay comprising the portion of the e-mail is generated for display over the television program, and wherein the overlay is part of the interactive program guide.20. The method of claim 19 , further comprising:generating for display within the overlay comprising the portion of the e-mail, a navigation option;receiving a user selection of the navigation option; andin response to receiving the user selection of the navigation option, changing a portion of the e-mail contained in the overlay.21. The method of claim 19 , wherein the overlay comprising the portion of the e-mail further comprises a second plurality of menu options claim 19 , and wherein the second plurality of menu options comprises a subset of the first plurality of menu options.22. The method of ...

TELEVISION CONTROL INTERFACE WITH ELECTRONIC GUIDE

An on-screen menu method and system for controlling the functions of integrated electronic devices and a television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel at each time during the day and an interconnected series of menus to control the features of the integrated electronic devices. An input device allows the viewer to move a pointer over different interactive areas of the guide and the function performed when the area is activated is displayed in a contextual help window. Various control glyphs provide for recursive interaction with the guide. 118-. (canceled)19. A method comprising:generating for display a plurality of program listings located within a boundary;determining whether a user-navigable cursor is moved to a location near an edge of the boundary; andgenerating information related to navigating the program listings, for display proximate to the cursor based on a location of the cursor, when the user-navigable cursor is moved to the location near the edge of the boundary.20. The method of claim 19 , further comprising:generating for display the information related to navigating the program listings in a window proximate to the cursor.21. The method of claim 20 , further comprising:removing the window from being displayed by fading the window.22. The method of claim 19 , further comprising:changing a shape of the user-navigable cursor, when the user-navigable cursor is moved to the location near the edge of the boundary.23. The method of claim 22 , wherein the shape of the user-navigable cursor is conditioned on the location of the user-navigable cursor.24. The method of claim 19 , further comprising:changing a display characteristic of the user-navigable cursor, when the user-navigable cursor is moved to the location near the edge of the boundary.25. The method of claim 19 , ...

DRUG ELUTING COMPOSITE

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. 1. A therapeutic-releasing device comprising: a first coated film;', 'a first therapeutic agent incorporated within the first coated film;', 'a first capping layer that substantially covers all of the first coated film and is impermeable to the first therapeutic agent; and', 'a first opening in the first capping layer; and, 'a first therapeutic-releasing construction including a second coated film;', 'a second therapeutic agent incorporated within the second coated film;', 'a second capping layer that substantially covers all of the second coated film and is impermeable to the second therapeutic agent; and', 'a second opening in the second capping layer,, 'a second therapeutic-releasing construction includingwherein the first therapeutic-releasing construction is stacked inside the second therapeutic-releasing construction.2. The therapeutic-releasing device of claim 1 , wherein the first therapeutic-releasing construction further includes a first elution pathway for the first therapeutic agent through the first coated film that exits the first coated film at the first opening.3. The therapeutic-releasing device of claim 2 , wherein the second therapeutic-releasing construction further includes a second elution pathway for the second therapeutic agent through the second coated film that exits the second coated film at the second opening.4. The therapeutic-releasing device of claim 3 , wherein the first coated film is a polymeric material comprising one or more polymeric barriers that are substantially impermeable to the first therapeutic agent and define the first elution pathway.5. The therapeutic-releasing device of claim 4 , wherein the second coated film is a polymeric material comprising ...

ROBUST BUILT-IN SELF TEST CIRCUITRY

Embodiments are directed to a semiconductor wafer having on-wafer circuitry. The on-wafer circuitry includes functional circuitry and first drive circuitry communicatively coupled to the functional circuitry. The on-wafer circuitry further includes test-only circuitry communicatively coupled to the functional circuitry, along with second drive circuitry communicatively coupled to the test-only circuitry. The control circuitry is communicatively coupled to the second drive circuitry and the test-only circuitry, wherein the first drive circuitry is configured to drive the functional circuitry in a first manner, and wherein the control circuitry is configured to control the second drive circuitry to drive the test-only circuitry in a second manner that is independent of the first manner. 1. A semiconductor wafer having on-wafer circuitry comprising:functional circuitry;first drive circuitry communicatively coupled to the functional circuitry;test-only circuitry communicatively coupled to the functional circuitry;second drive circuitry communicatively coupled to the test-only circuitry; andcontrol circuitry communicatively coupled to the second drive circuitry and the test-only circuitry;wherein the first drive circuitry is configured to drive the functional circuitry in a first manner;wherein the control circuitry is configured to control the second drive circuitry to drive the test-only circuitry in a second manner that is independent of the first manner.2. The semiconductor wafer of claim 1 , wherein the second manner comprises:receiving, at the control circuitry, control data from the test-only circuitry; generate modulated test-only drive signals; and', 'apply the modulated test-only drive signals to drive the test-only circuitry., 'based at least in part on the control data, controlling, using the control circuitry, the second test-only drive circuitry to3. The semiconductor wafer of claim 1 , wherein the second manner comprises:disabling the second drive ...

PERSONALIZED PRODUCTION OF BIOLOGICS AND METHOD FOR REPROGRAMMING SOMATIC CELLS

Use invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic and(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stern cells to be re-differentiated towards their somatic cell of origin so that the cells can he used to therapeutically treat an animal without resulting teratoma formation. 1. A method for producing an isolated nucleic acid or virus comprising transfecting a synthetically-produced Pluripotent Stent Cell (spPSC) with a vector that encodes and produces said nucleic acid or virus when transfected into said spPSC , and wherein the spPSC is produced from a cell of an animal.2. The method of further comprising immortalizing the transfected spPSC.3. The method of further comprising inducing differentiation of the transfected claim 2 , immortalized spPSCs.4. The method of further comprising inducing differentiation of the transfected spPSCs.5. The method of further comprising immortalizing the transfected claim 4 , differentiated spPSCs.6. The method of wherein the spPSC is selected from the group consisting of pluripotent stem cells produced from transfected non-Pluripotent Cells claim 1 , pluripotent stem cells produced by Somatic cell nuclear transfer (SCNT pluripotent stem cells) claim 1 , pluripotent stem cells produced by Altered nuclear transfer claim 1 , oocyte assisted reprogramming (ANT-OAR pluripotent stem cells) and pluripotent stem cells produced by parthenogenesis (PGA ...

METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE

Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity. 1. A method of treating disease-induced ataxia or non-ataxic imbalance in a human , the method comprising administering to the human a compound having nicotinic acetylcholine receptor activity.2. The method of wherein the compound is selected from the group consisting of donepezil claim 1 , exelon claim 1 , fluoxetine claim 1 , galantamine claim 1 , huperzine A claim 1 , MEM3454 claim 1 , MEM63908 claim 1 , tacrine claim 1 , XY4083 claim 1 , and combinations thereof.3. The method of wherein the method is for treating ataxia resulting from a disease selected from Spinocerebellar ataxia claim 1 , Friedriech's ataxia claim 1 , and fragile X/tremor ataxia syndrome.4. The method of wherein the method is for treating non-ataxic imbalance resulting from a disease selected from Spinocerebellar ataxia claim 1 , Friedriech's ataxia claim 1 , and fragile X/tremor ataxia syndrome.5. The method of wherein the method is for treating ataxia resulting from Spinocerebellar ataxia or fragile X/tremor ataxia syndrome.6. The method of wherein the method is for treating non-ataxic imbalance resulting from Spinocerebellar ataxia or fragile X/tremor ataxia syndrome. The present application claims the benefit of U.S. Provisional Application Ser. No. 61/041,069, filed on Mar. 31, 2008; Ser. No. 61/041,408, filed on Apr. 1, 2008; Ser. No. 61/043,522, filed on Apr. 9, 2008; Ser. No. 61/056,173, filed on May 27, 2008; and Ser. No. 61/076,343, filed on Jun. 27, 2008, each of which is hereby incorporated by reference herein in its entirety.The present disclosure generally relates to methods for treatment of disease-induced ataxia and non-ataxic imbalance. These symptoms can be treated in a patient by administering to the patient a compound having nicotinic acetylcholine receptor activity.The role of ...

TELEVISION CONTROL INTERFACE WITH ELECTRONIC GUIDE

An on-screen menu method and system for controlling the functions of integrated electronic devices and a television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel at each time during the day and an interconnected series of menus to control the features of the integrated electronic devices. An input device allows the viewer to move a pointer over different interactive areas of the guide and the function performed when the area is activated is displayed in a contextual help window. Various control glyphs provide for recursive interaction with the guide. 1. A method for navigating interactive program data , the method comprising:displaying in a first portion of a display screen a first plurality of program listings associated with a first time interval;displaying in a second portion of the display screen an interactive time bar that includes a series of interactive time indicator icons, each interactive time indicator icon representing a different time interval;receiving a selection of one of the displayed interactive time indicator icons; andin response to receiving the selection of the one of the interactive time indicator icons, displaying in the first portion of the display screen a second plurality of program listings associated with a second time interval, wherein the second time interval corresponds to the time interval represented by the selected interactive time indicator icon.2. The method of claim 1 , wherein the first time interval includes a current time.3. The method of claim 2 , wherein the time intervals represented by the time indicator icons include at least one of past and future time intervals.4. The method of wherein the interactive time bar is displayed in response to receiving a selection of a time bar activation icon.5. The method of wherein the interactive time bar is ...

ELECTRONIC DOCUMENT CONTENT CLASSIFICATION AND DOCUMENT TYPE DETERMINATION

A system and method includes receiving an electronic document having content divided into components and, for each of the components, comparing content of the component with component content characteristics of a classification schema associated with a document type and storing, in an electronic data storage, in a record associated with the component, indications of the component content characteristics of the classification schema that are included in the component. Document content characteristics of the classification schema are compared with the content of the electronic document and storing, in the electronic data storage, in a record for the electronic document, indications of the document content characteristics of the classification schema that are included in the electronic document. The electronic document is identified as the document type based on the content characteristics of the records meeting a document type criteria. 1. A processor-implemented method , comprising:receiving an electronic document having content divided into components;for each of the components, comparing content of the component with component content characteristics of a classification schema associated with a document type and storing, in an electronic data storage, in a record associated with the component, indications of the component content characteristics of the classification schema that are included in the component; the component content characteristics include at least one content characteristic in common with the document component characteristics, the component content characteristics including at least one content characteristic not included in the document component characteristics, and', 'the document component characteristics include at least one content component not included in the component content characteristics;, 'comparing document content characteristics of the classification schema with the content of the electronic document and storing, in the electronic ...

ELECTRONIC DOCUMENT CONTENT AUGMENTATION

A system and method includes obtaining content extracted from an electronic document, the electronic document having a document type. At least some of the content is transmitted to an online social networking system based on the document type. A recommended content change is received from the online social networking system. A user interface dynamically displays the recommended content change concurrently with display of the electronic document as the electronic document is updated. 1. A method , comprising operations performed with a processor , the operations comprising:obtaining content extracted from an electronic document, the electronic document having a document type;transmitting, via a network interface, at least some of the content to an online social networking system based on the document type;receiving, via the network interface, a recommended content change from the online social networking system; andcausing a user interface to dynamically display the recommended content change concurrently with display of the electronic document as the electronic document is updated.2. The method of claim 1 , the operations further comprising:receiving, via the user interface, a user selection of the recommended content change; andin response to receiving the selection, automatically applying the recommended content change to the electronic document.3. The method of claim 1 , wherein the document type includes a plurality of predetermined sections claim 1 , wherein the content corresponds to one of the predetermined sections claim 1 , and wherein the recommended content change includes a suggested change to words included in the one of the predetermined sections of the electronic document based on content from the online social networking system.4. The method of claim 3 , wherein the suggested change to the wording is at least one of: a replacement grammatical structure claim 3 , or a replacement word.5. The method of claim 1 , wherein the electronic document ...

ELECTRONIC DOCUMENT SUPPLEMENTATION WITH ONLINE SOCIAL NETWORKING INFORMATION

A system and method includes receiving content of an electronic document during a time the content is being entered into an electronic document by a user by via an electronic document editor application. A content characteristic is extracted from the content and transmitted to an online data source. A content item related to the content characteristic is received from the online data source. A user interface presents the content item concurrently with the electronic document editor application. 1. A processor-implemented method , comprising:receiving content of an electronic document during a time the content is being entered into an electronic document by a user by via an electronic document editor application;extracting a content characteristic from the content;transmitting the content characteristic to an online data source;receiving from the online data source, a content item related to the content characteristic; andcausing the user interface to present the content item concurrently with the electronic document editor application.2. The method of claim 1 , further comprising iteratively repeating the receiving claim 1 , extracting claim 1 , determining claim 1 , causing claim 1 , transmitting claim 1 , and receiving operations as new content is entered in to the electronic document.3. The method of claim 2 , further comprising causing the user interface to display in a section of a graphical user interface (GUI) information provided by the electronic document editor application until the content item is received from the online data source claim 2 , whereupon the user interface is caused to display the content item in the section of the GUI.4. The method of claim 3 , wherein the online data source is configured to provide a graphical appearance of the section of the GUI and wherein causing the user interface to present the content item comprises causing the user interface to display the content item in the section of the GUI according to the graphical ...

CLOUD EDGE APPLIANCES TO EXTEND CLOUD APPLICATIONS TO CUSTOMER PREMISES

A cloud edge appliance (CEA) may augment the providing, by a remote cloud service provider, of cloud applications to a customer. The CEA may be installed at the customer premises and may provide a local access point for the customer. In one implementation, the CEA may provide a cloud-based application to a number of user devices, the cloud-based application being associated with functions, in which at least a first portion of the functions are implemented by the CEA and at least a second portion of the plurality of functions are forwarded, over a wide area network, to the cloud service provider. 1. A server device comprising:a non-transitory memory device storing a set of computer-executable instructions; and provide, over a local network, a cloud-based application to a plurality of user devices, the cloud-based application being associated with a plurality of functions, wherein at least a first portion of the plurality of functions are implemented by the server device and at least a second portion of the plurality of functions are executed by a cloud service provider connected to the server device over a wide area network;', 'detect a network outage associated with a connection of the server device to the cloud service provider; and', 'establish, based on the detection of the network outage, a backup connection of the server device to the cloud service provider., 'a processor configured to execute the set of computer-executable instructions, wherein executing the set of computer-executable instructions causes the processor to2. The server device of claim 1 , wherein the server device is a cloud edge appliance (CEA) device claim 1 , and wherein executing the set of computer-executable instructions to establish the backup connection claim 1 , further causes the processor to:query other CEAs, that are reachable by the server device, to determine whether any of the other CEAs are connected to the cloud service provider; andestablish, when at least one other CEA is ...

INTRAMUSCULAR ATOVAQUONE FOR MALARIA PROPHYLAXIS

The present invention relates to the field of malaria. More specifically, the present invention provides compositions and methods useful for the prophylaxis and treatment of malaria, as well as other parasitic and fungal infections. In a specific embodiment, the present invention provides a method for preventing malaria comprising the step of intramuscularly administering an effective amount of atovaquone to a subject. 1. A method for preventing malaria comprising the step of intramuscularly administering an effective amount of atovaquone to a subject.2. The method of claim 1 , wherein the atovaquone is present as a microparticle.3. The method of claim 1 , wherein the atovaquone is administered once every two to eight weeks.4. A method for preventing a parasitic or fungal infection comprising the step of intramuscularly administering an effective amount of atovaquone to a subject.5. The method of claim 1 , wherein the atovaquone is present as a microparticle.6. The method of claim 1 , wherein the atovaquone is administered once every two to eight weeks.7Plasmodium, ToxoplasmaBabesiidaePneumocystis.. The method of claim 4 , wherein the parasitic infection is caused by or or wherein the fungal infection is caused by8. An intramuscularly-injectable formulation of a pharmaceutical composition comprising a microparticle formulation of atovaquone claim 4 , wherein the atovaquone is formulated for administration once every two to eight weeks.9. A kit comprising a first container comprising the intramuscularly-injectable formulation of ; a second container comprising a syringe; and instructions for injecting the formulation into a patient to prevent malaria.10. The kit of claim 9 , wherein the formulation is a lyophilized powder.11. The kit of claim 10 , further comprising a sterile liquid excipient. This application claims the benefit of U.S. Provisional Application No. 62/500,732, filed May 3, 2017, which is incorporated herein by reference in its entirety.The present ...

Small molecule proteasome activators and uses thereof

The disclosure is directed to compounds of the formula (I) and (II) and uses of such compounds to treat, among other conditions, neurodegenerative diseases and cancers.

SYSTEM AND METHOD FOR USING TELEVISION SCHEDULE INFORMATION

A television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel at each time during the day. An input device allows the viewer to browse through the schedule information area and/or obtain more information about programs of particular interest. In one aspect, the viewer may watch a program on the currently-tuned channel, while browsing through the other channels on a portion of the television screen. In another aspect, the viewer may watch programs currently being shown on the television, while he or she browses through the program guide. In yet another aspect, the system includes a database, a processor and associated software for automatically customizing the television schedule guide to an individual viewer or a group of viewers, e.g., a family, to facilitate use of the television schedule. 148-. (canceled)49. A system comprising:user input circuitry; and [ a first area comprising a plurality of selectable media asset identifiers;', 'a second area comprising a video corresponding to a first media asset; and', 'a third area comprising a video, wherein the video initially corresponds to a second media asset that (1) is different from the first media asset and (2) corresponds to a first media asset identifier of the plurality of selectable media asset identifiers, and wherein the video of the second media asset changes when the user indicates interest in a second media asset identifier of the plurality of selectable media asset identifiers; and, 'generate for simultaneous display, 'receive a user selection corresponding to the second area and the third area, wherein, when the user selection corresponds to the second area, sound corresponding to the second area is caused to be emitted, and wherein, when the user selection corresponds to the third area, sound corresponding to the third area is ...

METHOD AND STRUCTURES FOR PERSONALIZING LITHOGRAPHY

After printing common features from a primary mask into a photoresist layer located over a substrate, a functional feature which is suitable for changing functionalities or the configurations of the common features according to a chip design is selected from a library of additional functional features in a secondary mask. The selected functional feature from the secondary mask is printed into the photoresist layer to modify the common features that already exist in the photoresist layer. The selection and printing of functional feature processes can be repeated until a final image corresponding to the chip design is obtained in the photoresist layer. 1. A method for printing a pattern on a substrate comprising:providing a primary mask comprising common features of a chip at a given mask level;exposing a photoresist layer located on the substrate through the primary mask to print the common features in the photoresist layer;providing a secondary mask comprising a library of functional features for personalizing the common features in the photoresist layer at the given mask level according to a chip design;selecting a functional feature in the library of the functional features of the secondary mask to modify at least one common feature in the photoresist layer; andexposing the photoresist layer through the secondary mask to print the selected functional feature in the photoresist layer.2. The method of claim 1 , further comprising:selecting another functional feature in the library of the functional features of the secondary mask according to the chip design to modify at least one another common feature in the photoresist layer;exposing the photoresist layer through the secondary mask to print the selected another functional feature in the photoresist layer; andrepeating the above steps until personalized features according to the chip design are formed in the photoresist layer.3. The method of claim 2 , further comprising developing the photoresist layer after the ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 125.-. (canceled)26. A composition comprising:a low toxicity organic solvent selected from the group consisting of acetic acid, acetone, 1-butanol, 2-butanol, butyl acetate, dimethyl sulfoxide, ethanol, ethyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, methyl acetate, propylene glycol, acetonitrile, dioxane, formamide, dimethylformamide, pyridine, n-Methyl-2-pyrrolidone, methylpyrrolidone, dimethylacetamide, ethylene glycol, m ethyoxym ethanol, pyridine, piperidine, sulfolane, tetrahydrofuran, trichloroacetic acid, polyethylene glycol, and polyethylene oxide; anda fluorinated copolymer dissolved in the organic solvent, the fluorinated copolymer comprising tetrafluoroethylene and at least one functional group selected from the group consisting of acetate, alcohol, amine, and amide.27. The composition of claim 26 , further comprising a water phase suspended in the organic solvent as an emulsion.28. The composition of claim 27 , further comprising a therapeutic agent dissolved in the water phase.29. The composition of claim 26 , wherein the fluorinated copolymer is one of poly(tetrafluoroethylene-co-vinyl acetate) (TFE-VAc) claim 26 , poly(tetrafluoroethylene-co-vinyl alcohol) (TFE-VOH) claim 26 , and poly(tetrafluoroethylene-co-vinyl alcohol-co-vinyl[aminobutyraldehyde acetal]) (TFE-VOH-AcAm).30. The composition of claim 26 , wherein the fluorinated copolymer comprises up ...

COATED SUBSTRATE HAVING CORROSION RESISTANT COATING

A coated substrate made by a method that includes pre-treating a metal substrate, immersing the metal substrate in a trivalent chromium bath which does not contain hexavalent chromium, post-treating the coated metal substrate with an oxidizer, and curing the coated metal substrate in a controlled environment. 1. A coated substrate made by a method comprising:pre-treating a metal substrate such that a surface of the metal substrate is de-oxidized, wherein the metal substrate is selected from the group consisting of aluminum, zinc, cadmium, copper, silver, magnesium, tin, iron, aluminum based alloys, zinc based alloys, cadmium based alloys, copper based alloys, silver based alloys, magnesium based alloys, iron based alloys, and tin based alloys;immersing the metal substrate in a coating solution to produce a chromium-based coating on the metal substrate, wherein the coating solution comprises a trivalent chromium compound and a fluoride compound, but does not contain hexavalent chromium;removing the coated metal substrate from the coating solution;curing the chromium-based coating in a controlled environment containing a gaseous atmosphere to produce a hexavalent chromium enriched corrosion resistant coating on the metal substrate;post-treating the coated metal substrate with an oxidizer after removing the coated metal substrate from the coating solution, but before curing the coating; andexposing the coated metal substrate to ozone in the controlled environment.2. The coated substrate of claim 1 , wherein exposing the coated metal substrate to ozone in the controlled environment comprises exposing the coated metal substrate to 1 ppm ozone for one hour.3. The coated substrate of claim 1 , wherein exposing the coated metal substrate to ozone in the controlled environment comprises exposing the coated metal substrate to 0.1 ppm ozone for between four and twenty-four hours.4. The coated substrate of claim 1 , wherein the gaseous atmosphere has a relative humidity of over ...

DRUG COMPOSITION AND COATING

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein the particulate coating layer is formed by evaporation of a solution of the therapeutic agent and the at least one organic additive applied to the device to form a ...

ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. 1. A catheter-based implantable medical vascular device having a first diameter and a first surface area , and expandable to a second diameter and a second surface area within a vascular structure , in use;the device comprising at least one thixotropic, turbid, hydrogel material applied to at least a portion of said medical device, wherein the hydrogel material is applied to a surface of the device to create an applicated device of the first diameter and the first surface area;the hydrogel material comprising cyclodextrin, an aqueous solvent component and a polymer chain component, and at least one bioactive agent capable of treating vascular tissue upon release of said bioactive agent from said hydrogel material.2. The catheter-based implantable medical vascular device as claimed in claim 1 , the hydrogel material comprising a pharmacologically effective amount of the at least one bioactive agent claim 1 , wherein the polymer chain component comprises ethylene glycol units that form the hydrogel with the cyclodextrin claim 1 , wherein the cyclodextrin and the polymer chain unit self-assemble to form the hydrogel by spontaneous association and are present in the composition in respective amounts effective to make the hydrogel thixotropic.3. The catheter-based implantable medical vascular device of wherein catheter-based implantable medical vascular device is a nitinol wire reinforced expanded polytetrafluoroethylene-based vascular prosthesis.4. The catheter-based implantable medical vascular device of wherein catheter-based implantable medical vascular device is an endovascular angioplasty balloon.5. The catheter-based implantable medical vascular device of claim 1 , further comprising a ...

INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 130-. (canceled)32. (canceled)34. The compound of claim 31 , or a pharmaceutically acceptable salt thereof claim 31 , wherein Ris —NH claim 31 , —NHCH claim 31 , —OCH claim 31 , —CH claim 31 , or —CHOH.35. The compound of claim 31 , or a pharmaceutically acceptable salt thereof claim 31 , wherein Ris —OH claim 31 , —OCH claim 31 , —CHOH claim 31 , —CHNH claim 31 , —CH(OH)CH claim 31 , —CH claim 31 , or CHCH.37. (canceled)40. (canceled)41. The compound of claim 38 , or a pharmaceutically acceptable salt thereof claim 38 , wherein Ris hydrogen or —CH.4251-. (canceled)5456-. (canceled)5863-. (canceled)65. (canceled)66. A method of treating a disease comprising administering an effective amount of a compound of claim 64 , or pharmaceutically acceptable salt thereof claim 64 , to a subject in need thereof claim 64 , wherein the disease is inflammatory bowel disease or psoriasis. This application is a continuation of U.S. application Ser. No. 16/299,485, filed Mar. 12, 2019, the entire contents of which are hereby incorporated herein by reference. U.S. application Ser. No. 16/299,485 claims priority to U.S. Provisional Application No. 62/641,728, filed Mar. 12, 2018, the entire contents of which are hereby incorporated herein by reference.The Janus kinase (Jak) family is composed of four phosphotransferases, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2), each of which associates with a distinct set of cytokine receptors, mediating a cascade of autophosphorylation and subsequent activation of Signal Transducer and Activation of Transcription (STAT) proteins. Activated STATs dissociate from the cytokine receptor and translocate to the cell nucleus to regulate transcription of selected STAT-dependent pro-inflammatory genes. Disruption or ...

ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. 1. A method of treating a vascular condition comprising:providing a thixotropic, turbid, gel material containing at least one bioactive agent capable of treating vascular tissue in sufficient amounts to treat said vascular condition in said vascular tissue upon release of said bioactive agent from said gel material;administering said gel material to a vascular treatment site within an interior space of a blood vessel;allowing said gel material to remain at said vascular treatment site for a dwell time sufficient to release said bioactive agent from said gel material.2. The method of wherein said gel material does not occlude vascular structures upon introduction into flowing blood.3. The method of further comprising removing said gel material from within said blood vessel.4. The method of wherein said bioactive agent has one of anti-inflammatory properties and anti-proliferative properties.5. The method of wherein said bioactive agent is selected from the group consisting of dexamethasone claim 1 , estradiol claim 1 , carvedilol claim 1 , and cilostazol.6. The method of wherein said vascular disease is intimal hyperplasia.7. The method of wherein administrating said gel material includes injection through one of a needle-containing syringe claim 1 , a catheter claim 1 , and balloon.8. The method of wherein the gel material is applied to at least a portion of an outer surface of a medical device comprising one of a stent-graft and a balloon.9. A method of treating a vascular condition comprising:identifying a vascular structure in need of treatment or repair;isolating said vascular structure;applying means for stopping any blood flow in said vascular structure;providing a thixotropic, turbid, ...

METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE

Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity. 1. A method of treating disease-induced ataxia or non-ataxic imbalance in a human , the method comprising administering to the human a compound having nicotinic acetylcholine receptor activity.28-. (canceled)9. The method of wherein the compound is selected from the group consisting of donepezil claim 1 , exelon claim 1 , fluoxetine claim 1 , galantamine claim 1 , huperzine A claim 1 , MEM3454 claim 1 , MEM63908 claim 1 , tacrine claim 1 , XY4083 claim 1 , and combinations thereof.1019-. (canceled)20. The method of wherein the method is for treating ataxia resulting from a disease selected from Spinocerebellar ataxia claim 1 , Friedriech's ataxia claim 1 , and fragile X/tremor ataxia syndrome.21. The method of wherein the method is for treating non-ataxic imbalance resulting from a disease selected from Spinocerebellar ataxia claim 1 , Friedriech's ataxia claim 1 , and fragile X/tremor ataxia syndrome.22. The method of wherein the method is for treating ataxia resulting from Spinocerebellar ataxia or fragile X/tremor ataxia syndrome.23. The method of wherein the method is for treating non-ataxic imbalance resulting from Spinocerebellar ataxia or fragile X/tremor ataxia syndrome. The present application claims the benefit of U.S. Provisional Application Ser. No. 61/041,069, filed on Mar. 31, 2008; Ser. No. 61/041,408, filed on Apr. 1, 2008; Ser. No. 61/043,522, filed on Apr. 9, 2008; Ser. No. 61/056,173, filed on May 27, 2008; and Ser. No. 61/076,343, filed on Jun. 27, 2008, each of which is hereby incorporated by reference herein in its entirety.The present disclosure generally relates to methods for treatment of disease-induced ataxia and non-ataxic imbalance. These symptoms can be treated in a patient by administering to the patient a compound having nicotinic acetylcholine ...

QUINOLINE-BASED PROTEASOME INHIBITORS AND USES THEREOF

Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation. 5. The compound of claim 1 , wherein Ris hydrogen or lower alkyl.6. The compound of claim 5 , wherein Ris methyl or ethyl.7. The compound of claim 1 , wherein Ris cycloxexyl or cyclohexenyl.8. The compound of claim 1 , wherein Ris hydrogen claim 1 , lower alkyl claim 1 , or lower alkoxy.9. The compound of claim 8 , wherein Ris methyl or methoxy.10. The compound of claim 1 , wherein Ris hydrogen claim 1 , lower alkyl claim 1 , lower alkoxy claim 1 , N claim 1 ,N-dimethylamino or a heterocyclo group optionally containing one additional heteroatom.11. The compound of claim 10 , wherein Ris methyl claim 10 , isopropyl butyl or methoxy.12. The compound of claim 10 , wherein the heterocyclo group is a piperidinyl or a morpholinyl group.13. The compound of claim 1 , wherein Ris hydrogen claim 1 , lower alkyl or lower alkoxy.14. The compound of claim 13 , wherein Ris methyl or methoxy.16. A compound of having an ICof less than 10 μM.17. A pharmaceutical composition comprising one or more compounds of and one or more pharmaceutically acceptable excipients.18. A method for treating cancer comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.19. A method for treating an inflammatory disease comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.20. A method for modulating proteasome function comprising administering a therapeutically effective amount of at least one compound of to a subject in need thereof.21. The method of claim 19 , wherein the modulating comprises decreasing proteasome function by 5% to 100%. This application claims the benefit of priority of U.S. Provisional Appl. Ser. No. 62/479,805, filed Mar. 31, 2017, which is incorporated by reference as if fully set forth herein.This invention was ...

GLK GENES FOR IMPROVED FRUIT QUALITY

The present invention provides methods for improving fruit quality in plants that have low or reduced levels of Golden2-like (GLK) activity in the green fruit (e.g., cultivated tomato). The methods involve introgressing genes encoding functional GLKs into the plant so that they are expressed in the green fruit of the plant and thereby increase chloroplast biogenesis in the fruit. The plants of the invention have improved fruit quality, such as increased levels of starch, soluble solids, and/or sugars. 1. A method of preparing a cultivated tomato plant having fruit with increased sugar content , the method comprising:crossing a first parent cultivated tomato plant with a second parent tomato plant which expresses a functional Golden2-like nuclear transcription factor (GLK) protein in green fruit; andselecting offspring with increased GLK activity in the green fruit compared to the parent cultivated tomato plant.2Solanum pimpinellifolium.. The method of claim 1 , wherein the second parent tomato plant is3Solanum pennellii.. The method of claim I claim 1 , wherein the second parent tomato plant is4. The method of any one of to claim 1 , wherein the step of selecting the offspring is carried out by detecting a GLK gene encoding a functional GLK protein in the green fruit.5. A cultivated tomato plant made by the method of any one of to .6. A tomato plant comprising a heterologous nucleic acid sequence encoding a functional GLK that increases chloroplast biogenesis in green fruit of the plant compared to a control plant that lacks the nucleic acid sequence.7. The plant of claim 6 , wherein the plant is a cultivated tomato plant.8Solanum pimpinellifolium.. The plant of claim 7 , wherein the heterologous nucleic acid is from9Solanum pennellii.. The plant of claim 7 , wherein the heterologous nucleic acid is from This application claims benefit under 35 U.S.C. §119(e) to U.S. Application No. 61/546,934, filed Oct. 13, 2011, the contents of which are incorporated herein by ...

TELEVISION CONTROL INTERFACE WITH ELECTRONIC GUIDE

An on-screen menu method and system for controlling the functions of integrated electronic devices and a television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel at each time during the day and an interconnected series of menus to control the features of the integrated electronic devices. An input device allows the viewer to move a pointer over different interactive areas of the guide and the function performed when the area is activated is displayed in a contextual help window. Various control glyphs provide for recursive interaction with the guide. 118-. (canceled)19. A method for using an interactive program guide comprising:generating for display, over a television program, a display of the interactive program guide comprising a first plurality of menu options;receiving a user selection of a first menu option of the first plurality of menu options; andbased on receiving the user selection of the first menu option, generating for display, over the television program, an overlay comprising a portion of an electronic message authored by another user.20. The method of claim 19 , further comprising:generating for display within the overlay comprising the portion of the electronic message, a navigation option;receiving a user selection of the navigation option; andbased on receiving the user selection of the navigation option, changing the portion of the electronic message contained in the overlay.21. The method of claim 19 , wherein the overlay comprising the portion of the electronic message further comprises a second plurality of menu options claim 19 , and wherein the second plurality of menu options comprises a subset of the first plurality of menu options.22. The method of claim 21 , further comprising:generating for display a first portion of the second plurality of menu options along a ...

TELEVISION CONTROL INTERFACE WITH ELECTRONIC GUIDE

An on-screen menu method and system for controlling the functions of integrated electronic devices and a television schedule system and method for displaying television schedule information on a television screen includes a program guide having a schedule information area that depicts the programs that are being presented on each channel, at each time during the day and an interconnected series of menus to control the features of the integrated electronic devices. An input device allows the viewer to move a pointer over different interactive areas of the guide and the function performed when the area is activated is displayed in a contextual help window. Various control glyphs provide for recursive interaction with the guide. 118-. (canceled)19. A method for navigating media asset information , the method comprising:receiving media asset identifier information via a communications interface;storing the media asset identifier information in a database stored in a memory;generating for display an interactive time bar comprising a first interactive time indicator icon and a second interactive time indicator icon of a series of interactive time indicator icons, wherein the first interactive time indicator icon is associated with a first time interval, and wherein the second interactive time indicator icon is associated with a second time interval that does not overlap the first time interval;receiving, from a user input interface, a first user input comprising a selection of the first interactive time indicator icon associated with the first time interval; retrieving data representing the first time interval associated with the first interactive time indicator icon;', 'identifying, based on the retrieved data representing the first time interval, a first plurality of media asset identifiers associated with the first time interval from the media asset identifier information stored in the database stored in the memory;', 'retrieving the identified first plurality of media ...

Process Control of Electron Beam Wire Additive Manufacturing

A method of controlling operation of an electron beam gun and wire feeder during deposition of pools of molten matter onto a substrate to form beads upon solidification of the molten matter. The method includes providing a substrate and a wire source. A molten pool of liquid phase metal is formed on the substrate by melting the wire utilizing an electron beam generated by an electron beam gun. The liquid metal solidifies into a solid phase. A controller utilizes data from a sensor to adjust a process perimeter based, at least in part, on data generated by the sensor. 1. A method of controlling operation of an electron beam gun and wire feeder during a deposition process including deposition of pools of molten metal onto a substrate to form beads upon solidification of the molten metal , the method comprising:providing a substrate;providing a wire source that feeds wire at a wire feed rate;moving the electron beam gun and/or the wire feeder relative to the substrate at a travel speed;forming a molten pool of liquid phase metal on the substrate by melting wire utilizing an electron beam generated by an electron beam gun at a beam power;cooling the liquid phase metal to form a solidified deposit;utilizing a sensor to generate data related to at least one of: 1) a thermal transient; 2) wire alloy physical properties and/or melting range; 3) a width of the molten pool; 4) tracking of the wire and/or the molten pool; and 5) flaws in the solidified metal; andadjusting a deposition process parameter based, at least in part, on the data generated by the sensor.2. The method of claim 1 , including:adjusting a raster pattern of the wire source and/or the electron beam to deflect back, or to the sides to spread heat, wherein the adjusting beam raster pattern is adjusted at speeds of at least about 5 Hz.3. The method of claim 1 , including:detecting changes in molten pool size and shape, wherein molten pool size and/or shape comprises at least one of pool width, pool length, ...

AUTOMATED DOCUMENT CONTENT MODIFICATION

Systems and methods may be used to present changes to a document on a user interface. A method may include receiving, on the user interface, a user input including an edit task to a first portion of a document. The method may include determining, using a processor, that a second portion of the document includes text changeable by the edit task. The method may include automatically performing the edit task on the second portion of the document within the user interface based on the determination. 1. A method comprising:receiving, on a user interface, a user input including an edit task to a first portion of a document, the edit task including a change to text in the first portion of the document;determining, using a processor, that a second portion of the document includes text changeable by the edit task by matching a pattern of text in the second portion of the document to the text in the first portion of the document, the text in the second portion of the document differing from the text in the first portion of the document; andautomatically performing the edit task on the second portion of the document within the user interface based on the determination.2. The method of claim 1 , further comprising:based on the determination, presenting a selectable user interface component within the user interface, the selectable user interface component including an option to automate the edit task on the second portion of the document; andwherein automatically performing the edit task includes automatically performing the edit task in response to receiving, on the selectable user interface component, a user selection of the option to automate the edit task on the second portion of the document.3. The method of claim 1 , wherein the edit task includes a format change or a string change to the text in the first portion of the document.4. The method of claim 1 , wherein determining that the second portion of the document includes text changeable by the edit task includes ...

COMPOSITIONS AND METHODS FOR PREPARING COPPER-CONTAINING PAPER AND USES THEREOF

The invention comprises an environmentally benign method for the direct in situ preparation of copper nanoparticles (CuNPs) in paper by reducing sorbed copper ions with ascorbic acid. Copper nanoparticles were quickly formed in less than 10 minutes and were well distributed on the paper fiber surfaces. Paper sheets were characterized by x-ray diffraction, scanning electron microscopy, energy dispersive x-ray spectroscopy, and atomic absorption spectroscopy. Antibacterial activity of the CuNP sheets was assessed for by passing bacteria suspensions through the papers. The effluent was analyzed for viable bacteria and copper release. The CuNP papers with higher copper content showed a high bacteria reduction of log 8.8 for The paper sheets containing copper nanoparticles were effective in inactivating the test bacteria as they passed through the paper. The copper levels released in the effluent water were below the recommended limit for copper in drinking water (1 ppm). 1. A method of preparing a point-of-use water purification system comprising copper-containing paper , the method comprising:contacting an absorbent cellulose blotting paper or filter paper with an alkaline solution of copper hydroxide and soaking the paper in said solution, wherein copper is sorbed onto the paper;removing the paper from the copper hydroxide solution and then contacting the paper with deionized water to remove excess base;following removing the excess base, reducing copper ions embedded in the paper by contacting the paper with an ascorbic acid solution;removing the paper from ascorbic acid solution; andwashing the paper with deionized water,thereby preparing the point-of-use water purification system.2. The method of claim 1 , wherein the paper comprises bleached softwood kraft pulp and a thickness of about 0.1 millimeters (mm) to about 3.0 mm and a grammage of about 10 g/meter(m) to about 1 claim 1 ,000 g/ m.3. The method of claim 2 , wherein the paper has a thickness of about 0.5 mm. ...

Filtration structure for carbon dioxide scrubber

Disclosed is a filtration structure, comprising: a substrate, wherein the substrate is a three-dimensional lattice formed from repeating geometric shapes; a layer of porous material bonded over the substrate; and a liquid amine retained within the pores of the porous material. Also disclosed is a carbon dioxide scrubber comprising the filtration structure.

Facial movement and expression detection and stimulation

The disclosure features systems and methods for detecting a user's facial movement and expression, that include a plurality of radiation sources, a plurality of radiation detectors, where each radiation detector is paired with a different one of the radiation sources and configured to detect radiation emitted by its paired radiation source, and a controller connected to the radiation detectors and configured to receive signals corresponding to measurements of emitted radiation from each of the radiation detectors, determine, for each radiation source-detector pair, information about whether a radiation path between the source and detector is blocked by a portion of the user's face, and determine a facial movement or expression of the user based on the information.

DRUG COMPOSITION AND COATING

According to the invention there is provided inter alfa a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A medical device according to wherein the particulate coating layer is formed by evaporation of a solution of the therapeutic agent and the at least one organic additive applied to the device to form a solid particulate composition.3. (canceled)4. A medical device according to wherein the solution of the therapeutic agent and the at least one organic additive is a solution in a solvent selected from water claim 2 , acetone and mixtures thereof.5. A medical device ...

QUINOLINE-BASED PROTEASOME INHIBITORS AND USES THEREOF

Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation. 1. A compound of the formula II:wherein:{'sub': '6', 'Ris hydrogen, alkyl or aryl;'}{'sub': '7', 'Ris hydrogen, alkyl, alkenyl, cycloalkyl, aryl, cycloheteroalkyl or alkoxy;'}{'sub': '8', 'Ris hydrogen, halogen, or alkyl;'}{'sub': '9', 'Ris hydrogen, halogen, hydroxy, alkyl, alkoxy, aminoalkyl or heterocyclyl; and'}{'sub': '10', 'Ris hydrogen, halogen, lower alkyl, or lower alkoxy.'} This application is a continuation of U.S. patent application Ser. No. 15/940,133, filed Mar. 29, 2018, which application claims the benefit of priority of U.S. Provisional Appl. Ser. No. 62/479,805, filed Mar. 31, 2017, both of which are incorporated by reference as if fully set forth herein.This invention was made with government support under CHE1265738 awarded by the National Science Foundation. The government has certain rights in the invention.The human proteasome may be a target for the treatment of cancers such as multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma (MCL). Current therapeutics for these diseases include compounds that target the proteasomes in the cancerous cells. However, the available therapeutic compounds are competitive inhibitors that bind through a covalent and irreversible (or slowly reversible) bond to the N-terminal threonine of the enzyme's catalytic sites. And unfortunately, more than 97% of multiple myeloma patients develop resistance or become intolerant to the currently available competitive inhibitors within a few years, after which survival is often less than one year. Further, examples of small molecules that act as non-competitive proteasome inhibitors are very scarce and exhibit activity only at high micromolar concentrations or non-physiologically relevant concentrations.Described herein are compounds that can be useful for overcoming the types of acquired resistance often exhibited ...

DRUG COATED BALLOONS AND TECHNIQUES FOR INCREASING VASCULAR PERMEABILITY

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement and/or angle on the outer surface of the balloon. 1. A medical device comprising:a balloon comprising an outer surface; anda drug coating layer on the outer surface of the balloon,wherein the drug coating layer comprises microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement on the outer surface of the balloon.2. The medical device of claim 1 , wherein the microcrystals have a random and a substantial absence of uniformity in angles from the outer surface of the balloon.3. The medical device of claim 1 , wherein the drug coating comprises paclitaxel.4. The medical device of claim 1 , wherein the outer surface of the balloon comprises a non-porous polymer.5. The medical device of claim 1 , wherein the outer surface of the balloon comprises a porous polymer.6. The medical device of claim 1 , wherein the balloon comprises a layer material claim 1 , wherein the layered material comprises a polymer layer adhered to a fluoropolymer layer comprising a porous microstructure claim 1 , wherein layers are in overlying relationship to each other and the fluoropolymer layer is an outermost layer.7. The medical device of claim 6 , wherein the drug coating layer penetrates the outer surface of the balloon by an average penetration depth of from 2 to 10 m.8. A medical balloon comprising:a thermoplastic polymeric layer defining an interior chamber;a polymeric layer over at least a portion of the thermoplastic ...

Transalkylation Process and Catalyst Composition Used Therein

The present disclosure relates to a process for producing a mono-alkylated aromatic compound, such as, for example, ethylbenzene or cumene, in which an alkylatable aromatic compound stream, such as, for example, benzene, and an alkylation agent stream, such as, for example, poly-ethylbenzene or poly-isopropylbenzene, are contacted in the presence of a transalkylation catalyst and under at least partial liquid phase transalkylation conditions. The transalkylation catalyst comprises a zeolite having a framework structure selected from the group consisting of FAU, BEA*, MOR, MWW and mixtures thereof. The zeolite has a silica-alumina molar ratio in a range of to . The transalkylation catalyst composition has an external surface area/volume ratio in the range of 30 cmto 85 cm. 120-. (canceled)21. A process for producing ethylbenzene or cumene comprising the steps of:{'sup': −1', '−1, '(a) providing an transalkylation catalyst composition to a reaction zone, said transalkylation catalyst comprising a zeolite having a framework structure selected from the group consisting of FAU, BEA*, MOR, MWW and mixtures thereof, wherein the silica-alumina molar ratio of said zeolite is in a range of 10 to 15, wherein said transalkylation catalyst composition is in the form of an extrudate having an external surface area/volume ratio in the range of 30 cmto 85 cm;'}(b) providing a stream comprising a poly-alkylated benzene and a portion of an alkylatable aromatic compound stream to said reaction zone, wherein said poly-alkylated benzene stream comprises di-ethylbenzene or di-isopropylbenzene and said alkylatable aromatic compound stream comprises benzene;(c) contacting said poly-alkylated benzene stream with said alkylatable aromatic compound stream in the presence of said transalkylation catalyst composition under at least partial liquid phase transalkylation conditions to alkylate the alkylatable aromatic compound and produce a transalkylation effluent stream comprising ethylbenzene ...

Electrical neural blockade and functional stimulation of dysfunctional or transferred nerves

Methods and devices are provided for electrical neural blockade and stimulation of dysfunctional or transferred nerves. For example, a method is provided including identifying a dysfunctional or transferred nerve, attaching an electrode array to the dysfunctional or transferred nerve proximal to the target musculature, delivering an electrical neural blockade signal, and stimulating the dysfunctional or transferred nerve distal to the point of neural blockade. A system is also provided with an electrode array configured to attach proximally to a dysfunctional or transferred nerve and deliver an electrical neural blockade signal with a neuromuscular stimulating electrode array placed distal to the point of neural blockade, and a processor in communication with the electrode arrays and configured to provide stimulation instructions based on the detected activity of the other neuromusculature. A method is further provided for identifying and treating dysfunction arising from aberrant neural regeneration for which contralateral paired neuromusculature exists.

Nonlinear optical guided mode resonance filter

Nonlinear optical filters and associated methods. In a representative embodiment, a nonlinear optical filter includes a grating and a dye-doped polymer layer coupled to the grating. The dye-doped polymer layer may include ionic self-assembled layers. An associated method includes: providing a nonlinear filter comprising a grating and a dye-doped polymer layer coupled to the grating, directing an input broadband optical wave upon the filter, and backward diffracting the broadband optical wave from the grating as an output narrowband optical wave. The output narrowband optical wave may include a second harmonic beam.

Field grading members, cables having field grading members, and methods of making field grading members

A field grading composite body includes a polymeric matrix and a particulate filler distributed within the polymeric matrix. Particles of the particulate filler include a core formed from a semiconductor material, an oxide mixed layer deposited on the core, and conducting oxide layer. The conducting oxide layer deposited on the oxide mixed layer to provide an electrical percolation path through the polymeric matrix triggered by strength of an electric field extending through the field composite body. Conductors and methods of making field grading composite bodies for conductors are also described.

Zeolite SSZ-26

A crystalline zeolite SSZ-26 is prepared using a hexamethyl [4.3.3.0] propellane-8,11-diammonium cation as a template. Also disclosed is a process for converting hydrocarbons with crystalline zeolite SSZ-26.

Method of imaging an article

A method of imaging an article comprising a metal/metal oxide imageable layer with a laser beam. In particular, the present invention relates to a method for imparting a color image on the article. The method includes: a) providing an article including a substrate and an imageable layer, the imageable layer comprising a metal/metal oxide layer; b) imagewise applying a laser beam to the article; and c) in the portion of the article having the laser applied thereto, imparting a color to the metal/metal oxide layer different from the color in the non-imaged portion. Preferably, the imageable layer comprises aluminum/aluminum oxide. Also presented are imageable articles, and the resulting imaged articles.

Silica-modified aluminophosphate compositions, catalysts, method of preparing same and polymerization processes

An amorphous aluminophosphate composition is provided which exhibits a microstructure of sheets and spheres of silica-modified aluminophosphate. Also provided is a method for preparing the composition comprising mixing an aqueous solution containing aluminum ions, phosphate ions and silica ions, with a neutralizing solution, wherein the mixing is conducted with sufficient shear to produce on a microlevel, sheets of silica-modified aluminophosphate and spheres of silica-modified aluminophosphate. A polymerization catalyst and a polymerization process are also provided.

Powders of silica-oxide and mixed silica-oxide and method of preparing same

Silica powders and mixed silica-oxide powders and methods of preparing such powders for use as catalyst supports for polymerization processes.

A process for the polymerization of alpha olefins using a new aluminophosphate support

Novel catalysts are provided for the polymerization of olefins such as ethylene. These catalysts comprise a novel amorphous aluminophosphate comprising, on a microlevel, sheets of aluminophosphate as well as spheres of aluminophosphate plus a chromium compound. These new catalysts are surprisingly active; result in more co-monomer incorporation than prior art catalysts and reduce the amount of low molecular weight material in the product.

Aluminophosphates and their method of preparation

Disclosed is a new aluminophosphate composition which is (i) amorphous; (ii) has, on a microlevel, sheets of aluminophosphate as well as spheres. The new composition can be made, in one embodiment, by neutralizing a mixture of aluminum cations and phosphate anions with a base with vigorous mixing including shear forces sufficient to result in the formation of a mixture of sheets and spheres of aluminophosphate on a microlevel.

Process for the polymerization of alpha olefins using a new aluminophosphate support

Novel catalysts are provided for the polymerization of olefins such as ethylene. These catalysts comprise a novel amorphous aluminophosphate comprising, on a microlevel, sheets of aluminophosphate as well as spheres of aluminophosphate plus a chromium compound. These new catalysts are surprisingly active; result in more co-monomer incorporation than prior art catalysts and reduce the amount of low molecular weight material in the product.

Process for the polymerization of alpha olefins using a new aluminophosphate support

Novel catalysts are provided for the polymerization of olefins such as ethylene. These catalysts comprise a novel amorphous aluminophosphate comprising, on a microlevel, sheets of aluminophosphate as well as spheres of aluminophosphate plus a chromium compound. These new catalysts are surprisingly active; result in more co-monomer incorporation than prior art catalysts and reduce the amount of low molecular weight material in the product.

Process for the polymerization of alpha olefins using a new aluminophosphate support

Novel catalysts are provided for the polymerization of olefins such as ethylene. These catalysts comprise a novel amorphous aluminophosphate comprising, on a microlevel, sheets of aluminophosphate as well as spheres of aluminophosphate plus a chromium compound. These new catalysts are surprisingly active; result in more co-monomer incorporation than prior art catalysts and reduce the amount of low molecular weight material in the product.

Carbon-containing molybdenum and tungsten sulfide catalysts

Catalysts comprising a carbon-containing sulfide of molybdenum or tungsten are prepared by contacting, in the presence of sulfur, hydrogen and a hydrocarbon, ammonia and ammonium substituted molybdate, thiomolybdate, tungstate and thiotungstate salts at a temperature of from about 200°-600° C. These catalysts are useful for hydrotreating reactions. In a preferred embodiment, these catalysts will be promoted with certain transition metal sulfides, such as cobalt sulfide, which results in catalysts having greater activity than conventional catalysts such as cobaltmolybdate on alumina.

Transition metal sulfide promoted molybdenum or tungsten sulfide catalysts and their uses for hydroprocessing

ABSTRACT OF THE DISCLOSURE Hydrocarbon feeds are upgraded by contacting a feed, at elevated temperature and in the presence of hydrogen, with a self-promoted catalyst prepared by heating one or more catalyst precursors under oxygen-free conditions in the presence of sulfur at a temperature of at least about 150°C. The catalyst pre-cursors will be one or more compounds of the formula (ML)(MoyW1-yS4) wherein M comprises one or more di-valent promoter metals selected from the group con-sisting of Ni, Co, Zn, Cu and mixtures thereof, wherein y is any value ranging from 0 to 1 and wherein L is one or more neutral, nitrogen-containing ligands at least one of which is a chelating, polydentate ligand.

System and method of vehicular collision avoidance

Systems and methods are provided for acquiring and analyzing vehicle operation data in conjunction with traffic light information to manage traffic and avoid collisions. A traffic management system determines whether a vehicle is likely to be involved in a collision, based on at least vehicle operation data and the status of traffic lights. If it is determined that a vehicle is likely to be involved in a collision, the traffic management system may issue a notification or warning to the vehicle, e.g., instructing the vehicle to increase or decrease its rate of acceleration, and/or apply its brakes. Where the vehicle does not respond to the notification or warning, the traffic management system may take control of the vehicle, and notify and warn other vehicles and/or systems of its actions. Where the vehicle responds to the notification or warning, the traffic management system may calculate and recommend an insurance benefit.

Carbon-containing molybdenum and tungsten sulfide catalysts

Catalysts comprising a carbon-containing sulfide of molybdenum or tungsten are prepared by contacting, in the presence of sulfur, hydrogen and a hydrocarbon, ammonia and ammonium substituted molybdate, thiomolybdate, tungstate and thiotungstate salts at a temperature of from about 200°-600° C. These catalysts are useful for hydrotreating reactions. In a preferred embodiment, these catalysts will be promoted with certain transition metal sulfides, such as cobalt sulfide, which results in catalysts having greater activity than conventional catalysts such as cobalt-molybdate on alumina.

Amorphous, iron promoted Mo and W sulfide hydroprocessing catalysts and uses thereof

Hydrocarbon feeds are upgraded by contacting a feed, at elevated temperature and in the presence of hydrogen, with a catalyst comprising an amorphous sulfide of iron and a metal selected from the group consisting of Mo, W and mixture thereof. The catalysts are prepared by heating one or more catalyst precursor salts under oxygen-free conditions in the presence of sulfur at a temperature of at least about 250° C. The precursor salts will contain a thiometallate anion of Mo, W or mixture thereof and a cation comprising iron as a promoter metal and, optionally, additional divalent promoter metals, wherein said promoter metal or metals are chelated by at least one neutral, nitrogen-containing polydentate liquid and wherein said additional promoter metal is selected from the group consisting of Ni, Co, Mn, Zn, Cu and mixture thereof.

Turbine nozzle and related casting method for optimal fillet wall thickness control

In a method of investment casting a turbine nozzle which includes an outer band, an inner band and an airfoil section extending between the inner and outer bands, an improvement including shaping a temporary wax form, and external shell and internal core components used in casting such that during pouring of molten metal into a space created by removal of the wax form, shell material lies on opposite sides of an outer fillet connecting the outer band to the airfoil section. The resulting gas turbine nozzle includes first and second horizontally oriented ribs extending about interior peripheries of the airfoil section vertically adjacent the outer and inner band fillets.

Method to ameliorate osteolysis and metastasis

Materials immunoreactive with parathyroid hormone-related protein (PTH-rp) are used in the invention method to prevent and treat cancer metastasis to bone and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. Antibodies with human characteristics are included in the invention for application of the invention method to human subjects.

Compositions and methods for treating cardiovascular disease

The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

Composition to ameliorate osteolysis and metastasis

A therapeutically effective amount of an antibody for a compound selected from the group consisting of PTHrp, TGFα, IL-1α, IL-1β, IL-6, Lymphotoxin, TNF, PGE; 1,25 dihydroxy vitamin D3 and an antigenic fragment thereof used in the treatment of cancer metastasis to bone and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. An antibody immunoreactive with parathyroid hormone-related protein (PTHrp) is particularly preferred. Antibodies with human characteristics are included in the invention for application of the invention method to human subjects. Also, the antibody can be administered in an injectable formulation in combination with a therapeutically effective amount of a bisphosphonate or pyrophosphate having general structure formula (I), wherein X is a linking moiety allowing for the interconnection of the phosphonate groups, and pharmaceutically acceptable salts, hydrates and partial hydrates thereof. The antibody and bisphosphonate act synergistically in the treatment of cancer metastases to bone and symptomatic sequelae thereof and particularly as regards bone resorption.

Articles and methods of treating vascular conditions

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel 5 material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. 4709060) (GHMaierS) PI80S.AU.1

Articles and methods of treating vascular conditions

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.

Glk genes for improved fruit quality

The present invention provides methods for improving fruit quality in plants that have low or reduced levels of Golden2-like (GLK) activity in the green fruit (e.g., cultivated tomato). The methods involve introgressing genes encoding functional GLKs into the plant so that they are expressed in the green fruit of the plant and thereby increase chloroplast biogenesis in the fruit. The plants of the invention have improved fruit quality, such as increased levels of starch, soluble solids, and/or sugars.

GLK genes for improved fruit quality

The present invention provides methods for improving fruit quality in plants that have low or reduced levels of Golden2-like (GLK) activity in the green fruit (e.g., cultivated tomato). The methods involve introgressing genes encoding functional GLKs into the plant so that they are expressed in the green fruit of the plant and thereby increase chloroplast biogenesis in the fruit. The plants of the invention have improved fruit quality, such as increased levels of starch, soluble solids, and/or sugars.

Method for making an electronics module having air bridge protection without large area ablation

In a method for preserving an air bridge structure on an integrated circuit chip, without sacrificing metallization routing area in an overlying high density interconnect structure, a protective layer is sublimed over the air bridge to provide mechanical strength while preventing contamination and deformation during processing. A high density interconnect structure is applied over the chip and protective layer. A small portion of the high density interconnect structure is removed from the area over the air bridge structure, and the protective layer is then sublimed away, leaving the resultant structure with an undamaged air bridge which is free of residue.

Inhibition of hemoflagellates by camptothecin compounds

Camptothecin compounds are effective inhibitors of hemoflagellate growth and are useful in treating leishmaniasis and trypanosomiasis in livestock, other domestic animals and humans.

Drug eluting composite

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Drug eluting composite

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Drug eluting composite

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Eluting medical devices

The invention is directed to eluting medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

Retractable sheath devices, systems, and methods

The invention is directed to delivery medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises retractable sheath comprising neckable elements. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and a retractable outer sheath with a selectively permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during retraction of the outer sheath, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

Drug coated balloon

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a drug coating layer that primarily uses therapeutic agents alone for improving the quality of treatments in which drug coated balloons are utilized. Particular aspects may be directed to drug coated balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes at least one therapeutic agent and is substantially free of excipients.

Ocular device comprising a uv-absorbing benzotriazoles having a styrene group

A reactive monomer for preparing ultraviolet absorbing polymers has formula (I) wherein R 1 is a halogen or C 1 -C 6 straight or branched chain alkoxy group; and R 2 is a --(CH 2 ) 3 O--, --(CH 2 ) 2 O--, --CH(CH 3 )CH 2 O--, --CH 2 CH(CH 3 )O--, --(CH 2 ) 3 OCH 2 --, --(CH 2 ) 2 OCH 2 --, --CH(CH 3 )CH 2 OCH 2 --, or --CH 2 CH(CH 3 )OCH 2 -- group. The compound can be used to produce ultraviolet absorbing polymers, such as those used for ocular devices including contact and intraocular lenses.

BENZOTRIAZOLES THAT ABSORB UV RADIATION THAT HAVE A STYRENE GROUP.

UN MONOMERO REACTIVO PARA LA PREPARACION DE POLIMEROS ABSORBEDORES DE ULTRAVIOLETAS QUE TIENE LA FORMULA (I) EN LA QUE R{SUP,1} ES HALOGENO O UN GRUPO ALCOXI DE CADENA LINEAL O RAMIFICADA C{SUB,1}-C{SUB,6}; Y R{SUP,2} ES UN GRUPO (CH{SUB,2}){SUB,3}O-, -CH(CH{SUB,3}CH{SUB,2}O-, CH{SUB,2}CH(CH{SUB,3})O-, -(CH{SUB,2}){SUB,3}OCH{SUB,2}-, (CH{SUB,2}){SUB,2}OCH{SUB,2}-, -CH(CH{SUB,3})CH{SUB,2}OCH{SUB,2}O -CH{SUB,2}CH(CH{SUB,3})OCH{SUB,2}-. EL COMPUESTO SE PUEDE UTILIZAR PARA LA PRODUCCION DE POLIMEROS ABSORBEDORES DE ULTRAVIOLETAS, TALES COMO LOS UTILIZADOS EN DISPOSITIVOS OCULARES INCLUIDAS LAS LENTES DE CONTACTO Y LAS INTRAOCULARES. A REACTIVE MONOMER FOR THE PREPARATION OF ULTRAVIOLET ABSORBING POLYMERS THAT HAS THE FORMULA (I) IN WHICH R {SUP, 1} IS HALOGEN OR A LINEAR OR BRANCHED ALCOXI GROUP C {SUB, 1} -C {SUB, 6 }; YR {SUP, 2} IS A GROUP (CH {SUB, 2}) {SUB, 3} O-, -CH (CH {SUB, 3} CH {SUB, 2} O-, CH {SUB, 2} CH (CH {SUB, 3}) O-, - (CH {SUB, 2}) {SUB, 3} OCH {SUB, 2} -, (CH {SUB, 2}) {SUB, 2} OCH {SUB, 2} -, -CH (CH {SUB, 3}) CH {SUB, 2} OCH {SUB, 2} O -CH {SUB, 2} CH (CH {SUB, 3}) OCH {SUB, 2} - THE COMPOUND MAY BE USED FOR THE PRODUCTION OF ULTRAVIOLET ABSORBING POLYMERS, SUCH AS THOSE USED IN EYE DEVICES INCLUDING CONTACT LENSES AND INTRAOCULAR LENSES.

Chalcogenides of groups viii and viib

ABSTRACT OF THE DISCLOSURE Chalcogenides having a particle size of less than 0.1 micron and a crystallite size of about 50.ANG. x 100.ANG. or less of the formula MXy wherein M is ruthenium, rhodium, iridium or osmium, X is a chalcogenide selected from the group consisting of sulfur, selenium, tellurium and mixtures thereof, and y is a number ranging from about 0.1 to about 3 or M is technetium, rhenium or man-ganese and y is about 1.5 to about 4.

Television schedule system and method of operation for multiple program occurrences

An improved television guide system. According to one embodiment of the invention, television guide information is provided that includes multiple occurrences of a single show. The guide system of the present invention allows the user to identify a show and, thereafter, identify when the identified show will be played again. Accordingly, the user may more easily select shows for viewing or recordation.

Nitrogen removal from olefinic naphtha feedstreams to improve hydrodesulfurization versus olefin saturation selectivity

The instant invention relates to a two step process for producing low sulfur olefinic naphtha boiling range product streams through nitrogen removal and selective hydrotreating.

Enhanced oil recovery surfactant formulation and method of making the same

The present invention is directed to an enhanced oil recovery formulation which comprises: (a) an alkylaromatic sulfonate; (b) an isomerized olefin sulfonate (c) a solvent; (d) a passivator; and (e) a polymer.

Use of alpha-1c specific compounds to treat benign prostatic hyperplasia

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeuti-cally effective amount of a compound which binds to a human .alpha.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha.1A adrenergic receptor, a human .alpha.1B s adrenergic receptor and a human histamine H1 receptor, and, binds to a human .alpha.2 adrenergic receptor with a binding affin-ity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha.1C adrenergic re-ceptor, Compounds meeting these criteria are provided.

Inhibition of hemoflagellates by camptothecin compounds

Camptothecin compounds are effective inhibitors of hemoflagellate growth and are useful in treating leishmaniasis and trypanosomiasis in livestock, other domestic animals and humans.

Motilin homologs

The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonsits, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.

Zeolite ssz-26

ABSTRACT OF THE DISCLOSURE A crystalline zeolite SSZ-26 is prepared using a hexamethyl [4.3.3.0] propellane-8,11-diammonium cation as a template. Also disclosed is a process for converting hydrocarbons with crystalline zeolite SSZ-26.

Low ph mild personal cleansing bar

This invention is a mild personal cleansing bar comprising: from about 20 % to about 50 % lathering mild synthetic surfactant and from about 5 % to about 50 % of magnesium soap; wherein the ratio of said lathering mild synthetic surfactant to said soap is from about 10:1 to about 0.4:1; said bar having a pH of from about 6.5 to about 8.5 in a 1 % aqueous solution at 25 ·C.

Eluting medical devices

The invention is directed to eluting medical devices that enable consistent "on-demand" delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

Personalized production of biologics and method for reprogramming somatic cells

The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.